Free Trial
NYSE:AVNS

Avanos Medical (AVNS) Stock Price, News & Analysis

Avanos Medical logo
$18.68 -0.47 (-2.45%)
(As of 11/15/2024 ET)

About Avanos Medical Stock (NYSE:AVNS)

Key Stats

Today's Range
$18.66
$19.31
50-Day Range
$18.60
$24.69
52-Week Range
$17.39
$25.36
Volume
227,214 shs
Average Volume
267,453 shs
Market Capitalization
$858.53 million
P/E Ratio
54.94
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

Avanos Medical Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
77th Percentile Overall Score

AVNS MarketRank™: 

Avanos Medical scored higher than 77% of companies evaluated by MarketBeat, and ranked 273rd out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Avanos Medical are expected to grow by 31.82% in the coming year, from $1.32 to $1.74 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Avanos Medical is 54.94, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 111.54.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Avanos Medical is 54.94, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 67.98.

  • Price to Book Value per Share Ratio

    Avanos Medical has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Avanos Medical's valuation and earnings.
  • Percentage of Shares Shorted

    1.35% of the float of Avanos Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    Avanos Medical has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avanos Medical has recently decreased by 19.55%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Avanos Medical does not currently pay a dividend.

  • Dividend Growth

    Avanos Medical does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.35% of the float of Avanos Medical has been sold short.
  • Short Interest Ratio / Days to Cover

    Avanos Medical has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Avanos Medical has recently decreased by 19.55%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Avanos Medical has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Avanos Medical this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Avanos Medical insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.90% of the stock of Avanos Medical is held by insiders.

  • Percentage Held by Institutions

    95.17% of the stock of Avanos Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Avanos Medical's insider trading history.
Receive AVNS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.

AVNS Stock News Headlines

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Avanos Medical Launches New CORGRIP® SR
See More Headlines

AVNS Stock Analysis - Frequently Asked Questions

Avanos Medical's stock was trading at $22.43 on January 1st, 2024. Since then, AVNS stock has decreased by 16.7% and is now trading at $18.68.
View the best growth stocks for 2024 here
.

Avanos Medical, Inc. (NYSE:AVNS) issued its quarterly earnings data on Wednesday, July, 31st. The company reported $0.34 EPS for the quarter, beating the consensus estimate of $0.29 by $0.05. The company's quarterly revenue was up 1.4% compared to the same quarter last year.

Avanos Medical's top institutional investors include State Street Corp (3.96%), Geode Capital Management LLC (2.29%), Tributary Capital Management LLC (1.41%) and Charles Schwab Investment Management Inc. (1.14%). Insiders that own company stock include Michael Greiner and Julie Ann Shimer.
View institutional ownership trends
.

Shares of AVNS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Avanos Medical investors own include JPMorgan Chase & Co. (JPM), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Home Depot (HD), Netflix (NFLX) and Tesla (TSLA).

Company Calendar

Last Earnings
7/31/2024
Today
11/17/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/18/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical appliances & supplies
Sub-Industry
Medical Equipment
Fax
N/A
Employees
3,771
Year Founded
N/A

Profitability

Net Income
$-61,800,000.00
Pretax Margin
3.83%

Debt

Sales & Book Value

Annual Sales
$673.30 million
Cash Flow
$2.02 per share
Book Value
$26.76 per share

Miscellaneous

Free Float
44,624,000
Market Cap
$858.53 million
Optionable
Optionable
Beta
0.92
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NYSE:AVNS) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners